BIOMAT Database Logo BIOMAT Database Logo

A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. 1997

M Elkordy, and M Crump, and J J Vredenburgh, and W P Petros, and A Hussein, and P Rubin, and M Ross, and C Gilbert, and C Modlin, and B Meisenberg, and D Coniglio, and J Rabinowitz, and M Laughlin, and J Kurtzberg, and W P Peters
Duke University, Bone Marrow Transplant Program, Durham, NC, USA.

We studied the effects of escalating doses of recombinant human IL-1 beta in patients receiving high-dose chemotherapy and ABMT for metastatic breast cancer or malignant melanoma. Sixteen patients received IL-1 beta, 4 to 32 ng/kg/day administered subcutaneously for 7 days beginning 3 h after bone marrow infusion. Three patients at the highest dose level also received G-CSF following completion of IL-1 beta. All patients completed the 7 days of therapy. The majority of patients experienced chills and fever following one or more injections, and seven had severe pain at the injection site. There was one episode of hypotension and one episode of transient confusion at the highest dose level; other significant toxicity was not identified. Recovery of neutrophils to > 0.5 x 10(9)l and platelet transfusion independence occurred at a median of 23 and 22 days, respectively, which was comparable to historical controls. The mean number of bone marrow colony-forming unit granulocyte-macrophage (CFU-GM) per 10(5) mononuclear cells on day +21 post-ABMT was more than twice that of control patients or patients receiving G-CSF or GM-CSF. A linear correlation was found between the dose of IL-1 beta and endogenous concentrations of several cytokines. These patients also displayed significantly higher concentrations of endogenous G-CSF compared to historical controls receiving GM-CSF. While IL-1 beta was moderately toxic and had no effect on recovery of peripheral blood counts after ABMT, the increased number of bone marrow CFU-GM suggests that the addition of G- or GM-CSF to a short course of IL-1 beta may accelerate hematologic recovery.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003114 Colony-Forming Units Assay A cytologic technique for measuring the functional capacity of stem cells by assaying their activity. Clonogenic Cell Assay,Stem Cell Assay,Clonogenic Cell Assays,Colony Forming Units Assays,Colony-Forming Units Assays,Stem Cell Assays,Assay, Clonogenic Cell,Assay, Colony-Forming Units,Assay, Stem Cell,Assays, Clonogenic Cell,Assays, Colony-Forming Units,Assays, Stem Cell,Colony Forming Units Assay
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006412 Hematopoietic Stem Cells Progenitor cells from which all blood cells derived. They are found primarily in the bone marrow and also in small numbers in the peripheral blood. Colony-Forming Units, Hematopoietic,Progenitor Cells, Hematopoietic,Stem Cells, Hematopoietic,Hematopoietic Progenitor Cells,Cell, Hematopoietic Progenitor,Cell, Hematopoietic Stem,Cells, Hematopoietic Progenitor,Cells, Hematopoietic Stem,Colony Forming Units, Hematopoietic,Colony-Forming Unit, Hematopoietic,Hematopoietic Colony-Forming Unit,Hematopoietic Colony-Forming Units,Hematopoietic Progenitor Cell,Hematopoietic Stem Cell,Progenitor Cell, Hematopoietic,Stem Cell, Hematopoietic,Unit, Hematopoietic Colony-Forming,Units, Hematopoietic Colony-Forming

Related Publications

M Elkordy, and M Crump, and J J Vredenburgh, and W P Petros, and A Hussein, and P Rubin, and M Ross, and C Gilbert, and C Modlin, and B Meisenberg, and D Coniglio, and J Rabinowitz, and M Laughlin, and J Kurtzberg, and W P Peters
Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation.
December 1993, Blood,
M Elkordy, and M Crump, and J J Vredenburgh, and W P Petros, and A Hussein, and P Rubin, and M Ross, and C Gilbert, and C Modlin, and B Meisenberg, and D Coniglio, and J Rabinowitz, and M Laughlin, and J Kurtzberg, and W P Peters
Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma.
October 1995, Bone marrow transplantation,
M Elkordy, and M Crump, and J J Vredenburgh, and W P Petros, and A Hussein, and P Rubin, and M Ross, and C Gilbert, and C Modlin, and B Meisenberg, and D Coniglio, and J Rabinowitz, and M Laughlin, and J Kurtzberg, and W P Peters
High-dose chemotherapy with autologous bone marrow transplantation.
September 1984, Cancer,
M Elkordy, and M Crump, and J J Vredenburgh, and W P Petros, and A Hussein, and P Rubin, and M Ross, and C Gilbert, and C Modlin, and B Meisenberg, and D Coniglio, and J Rabinowitz, and M Laughlin, and J Kurtzberg, and W P Peters
Inflammatory peripheral neuropathy following high dose chemotherapy and autologous bone marrow transplantation.
September 1992, Bone marrow transplantation,
M Elkordy, and M Crump, and J J Vredenburgh, and W P Petros, and A Hussein, and P Rubin, and M Ross, and C Gilbert, and C Modlin, and B Meisenberg, and D Coniglio, and J Rabinowitz, and M Laughlin, and J Kurtzberg, and W P Peters
Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation.
May 1997, Clinical cancer research : an official journal of the American Association for Cancer Research,
M Elkordy, and M Crump, and J J Vredenburgh, and W P Petros, and A Hussein, and P Rubin, and M Ross, and C Gilbert, and C Modlin, and B Meisenberg, and D Coniglio, and J Rabinowitz, and M Laughlin, and J Kurtzberg, and W P Peters
Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure.
October 1994, Bone marrow transplantation,
M Elkordy, and M Crump, and J J Vredenburgh, and W P Petros, and A Hussein, and P Rubin, and M Ross, and C Gilbert, and C Modlin, and B Meisenberg, and D Coniglio, and J Rabinowitz, and M Laughlin, and J Kurtzberg, and W P Peters
High-dose chemotherapy and autologous bone marrow transplantation for myeloma.
January 1989, European journal of haematology. Supplementum,
M Elkordy, and M Crump, and J J Vredenburgh, and W P Petros, and A Hussein, and P Rubin, and M Ross, and C Gilbert, and C Modlin, and B Meisenberg, and D Coniglio, and J Rabinowitz, and M Laughlin, and J Kurtzberg, and W P Peters
Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
July 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Elkordy, and M Crump, and J J Vredenburgh, and W P Petros, and A Hussein, and P Rubin, and M Ross, and C Gilbert, and C Modlin, and B Meisenberg, and D Coniglio, and J Rabinowitz, and M Laughlin, and J Kurtzberg, and W P Peters
A phase I trial of high-dose diaziquone and autologous bone marrow transplantation: an Illinois Cancer Council study.
August 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Elkordy, and M Crump, and J J Vredenburgh, and W P Petros, and A Hussein, and P Rubin, and M Ross, and C Gilbert, and C Modlin, and B Meisenberg, and D Coniglio, and J Rabinowitz, and M Laughlin, and J Kurtzberg, and W P Peters
Transient nephrogenic diabetes insipidus following high-dose cyclophosphamide chemotherapy and autologous bone marrow transplantation.
February 1987, Cancer treatment reports,
Copied contents to your clipboard!